This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Jul 2012

Merck Signs Deals for Novel HIV Drug Candidates

Merck has signed licensing agreements with Chimerix Inc and Yamasa Corporation for two investigational HIV drug candidates.

Merck has signed two licensing agreements for investigational HIV drug candidates in a bid to develop a new treatment for the viral infection.


The first deal was signed with Chimerix Inc for an investigational oral nucleoside reverse transcriptase inhibitor called CMX157, which is currently undergoing phase-I testing.


Merck will now be responsible for developing and commercialising CMX157 around the world.


The second deal involves Japanese company Yamasa Corporation and a novel nucleoside reverse transcriptase inhibitor candidate called EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine), which is currently the subject of

Related News